Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494408 | 0.84 | LMNA (0.46) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3494391 | 0.83 | POLB (0.45) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3494027 | 0.83 | ALDH1A1 (0.56) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3495685 | 0.83 | LMNA (0.48) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3492404 | 0.82 | LMNA (0.44) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3493763 | 0.81 | LMNA (0.59) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3491750 | 0.80 | ALDH1A1 (0.46) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3492723 | 0.79 | ALDH1A1 (0.45) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3493022 | 0.78 | ALDH1A1 (0.48) | GAKLMNAHPGDBCAT2ALDH1A1 | |
| SCHEMBL3494702 | 0.78 | HPGD (0.47) | GAKLMNAHPGDBCAT2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3481399-A1 | METHODS FOR TREATMENT OF HEART FAILURE | Cardurion Pharmaceuticals, LLC (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018009899-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS, LLC (US) | 2018-01-11 | — | — | WO | disclosed |
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | GAK 1836/4885LMNA 3072/4885HPGD 310/4885 |
| US-10870656-B2 | Methods for treatment of heart failure | TNNT2, TNNI3, TNNC1 | GAK 3066/4885LMNA 1957/4885HPGD 188/4885 |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | GAK 2792/4885LMNA 4474/4885HPGD 437/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | GAK 2792/4885LMNA 4474/4885HPGD 437/4885 |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | TNNT2, TNNI3, TNNC1 | GAK 3066/4885LMNA 1957/4885HPGD 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.